Ohio State Navbar

AML Score That Combines Genetic and Epigenetic Changes May Help Guide Therapy

Currently, doctors use chromosome markers and gene mutations to determine the best treatment for a patient with acute myeloid leukemia (AML). But a new study suggests that a score based on seven mutated genes and the epigenetic changes that the researchers discovered were present might help guide treatment by identifying novel subsets of patients. The findings, published in the Journal of Clinical Oncology, come from a study led by researchers at the OSUCCC – James. Clara D. Bloomfield, MD, a Distinguished University Professor who also serves as OSU cancer scholar and senior adviser for the OSUCCC – James, was principal investigator for the study, and Guido Marcucci, MD, a professor in the Division of Hematology at Ohio State who also serves as associate director for translational research at the OSUCCC – James, was first author. Read More: